Apelin-36 (human) (TFA)

Apelin-36 (human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36 (human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61) . Apelin-36 (human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36 (human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ[1][2][3][4].

Product Specifications

UNSPSC

12352209

Target

Apelin Receptor (APJ) ; HIV

Type

Peptides

Related Pathways

Anti-infection; GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Infection; Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/apelin-36-human-tfa.html

Purity

99.42

Solubility

10 mM in DMSO

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(NCC(N2[C@@H](CCC2)C(NCC(N3[C@@H](CCC3)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CCC(N)=O)C(NCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC6=CC=CC=C6)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N7[C@@H](CCC7)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CC8=CNC=N8)C(N[C@@H](CCCCN)C(NCC(N9[C@@H](CCC9)C(N[C@@H](CCSC)C(N%10[C@@H](CCC%10)C(N[C@@H](CC%11=CC=CC=C%11)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N.OC(C(F)(F)F)=O

Molecular Formula

C186H298F3N69O45S

Molecular Weight

4309.85

References & Citations

[1]Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251 (2) :471-476.|[2]Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84 (5) :1162-1172.|[3]Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. Apelin peptides block the entry of human immunodeficiency virus (HIV) . FEBS Lett. 2000;473 (1) :15-18.